非小细胞肺癌治疗市场：按癌症类型、药物类别和分销管道划分 - 2023-2030 年全球预测

预计2023年全球非小细胞肺癌药物市场将大幅成长166.6亿美元，复合年增长率为7.74%，预计2030年将达到281.3亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球非小细胞肺癌治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.非小细胞肺癌治疗的全球市场规模与预测为何？

2.在预测期内，COVID-19对全球非小细胞肺癌治疗药物市场的阻碍因素与影响有哪些？

3. 在预测期内，全球非小细胞肺癌治疗市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球非小细胞肺癌药物市场的竞争策略是什么？

5.全球非小细胞肺癌药物市场的技术趋势与法律规范如何？

6.全球非小细胞肺癌治疗市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入非小细胞肺癌药物全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 空气污染和吸烟习惯的增加增加了全球非小细胞肺癌（NSCLC）的盛行率
    • 存在强大的非小细胞肺癌治疗药物管线
  • 抑制因素
    • 药品价格昂贵且难以取得
  • 机会
    • 介绍新的标靶治疗和治疗方法
    • 新兴国家引进先进治疗方法
  • 任务
    • 资本集中治疗和程序
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章小细胞肺癌治疗药物市场

• 腺癌
• 大细胞癌
• 鳞状细胞癌

第7章小细胞肺癌治疗药物市场

• 血管新生抑制剂
• 表皮生长因子受体阻断剂
• 叶酸拮抗
• 激酶抑制剂
• 微管稳定剂
• PD-1/PD-L1抑制剂

第8章小细胞肺癌治疗药物市场：按分销管道

• 医院药房
• 网路药房
• 零售药房

第9章北美和南美非小细胞肺癌治疗药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第10章亚太非小细胞肺癌治疗市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第11章欧洲、中东和非洲非小细胞肺癌药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第12章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

• 讨论指南
• 关于许可证和定价

The Global Non-small Cell Lung Cancer Therapeutics Market is forecasted to grow significantly, with a projected USD 16.66 billion in 2023 at a CAGR of 7.74% and expected to reach a staggering USD 28.13 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Non-small Cell Lung Cancer Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Non-small Cell Lung Cancer Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Cancer Type, market is studied across Adenocarcinoma, Large Cell Carcinoma, and Squamous Cell Carcinoma. The Squamous Cell Carcinoma is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, Microtubule Stabilizer, and PD-1/ PD-L1 Inhibitor. The Epidermal Growth Factor Receptor Blocker is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Non-small Cell Lung Cancer Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Non-small Cell Lung Cancer Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-small Cell Lung Cancer Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-small Cell Lung Cancer Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Non-small Cell Lung Cancer Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Non-small Cell Lung Cancer Therapeutics Market?

6. What is the market share of the leading vendors in the Global Non-small Cell Lung Cancer Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Non-small Cell Lung Cancer Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Non-small Cell Lung Cancer Therapeutics Market, by Cancer Type, 2022 vs 2030
• 4.3. Non-small Cell Lung Cancer Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.4. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel, 2022 vs 2030
• 4.5. Non-small Cell Lung Cancer Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of Non-small Cell Lung Cancer (NSCLC) across the globe due to increasing air pollution and smoking habits
    • 5.1.1.2. Presence of a strong pipeline for NSCLC therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and lack of availability of the drug
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new targeted therapies and treatments
    • 5.1.3.2. Adoption of advanced therapeutics in the developing countries
  • 5.1.4. Challenges
    • 5.1.4.1. Capital intensive treatment and procedures
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Non-small Cell Lung Cancer Therapeutics Market, by Cancer Type

• 6.1. Introduction
• 6.2. Adenocarcinoma
• 6.3. Large Cell Carcinoma
• 6.4. Squamous Cell Carcinoma

7. Non-small Cell Lung Cancer Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Angiogenesis Inhibitor
• 7.3. Epidermal Growth Factor Receptor Blocker
• 7.4. Folate Antimetabolites
• 7.5. Kinase Inhibitor
• 7.6. Microtubule Stabilizer
• 7.7. PD-1/ PD-L1 Inhibitor

8. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Non-small Cell Lung Cancer Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
• FIGURE 5. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET DYNAMICS
• FIGURE 9. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 5. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 9. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 147. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 148. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET LICENSE & PRICING